IDEXX Laboratories, Inc. IDXX
519.26
5.87
1.14%
as of 25 Sep
- Market cap
- $40.2B
- P/E
- 36.2×
Follow IDXX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
IDEXX Laboratories, Inc. (IDXX) Free cash flow margin
IDEXX Laboratories, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 27.2%, up 2.9 percentage points from fiscal 2025 (24.3%). Over the past ten years it has ranged from 8.67% (fiscal 2015) to 24.3% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 24.3% | 3.77 |
| FY2024 | 20.5% | (0.63) |
| FY2023 | 21.1% | 9.70 |
| FY2022 | 11.4% | (8.37) |
| FY2021 | 19.8% | (0.19) |
| FY2020 | 20.0% | 7.34 |
| FY2019 | 12.6% | 0.11 |
| FY2018 | 12.5% | (2.54) |
| FY2017 | 15.1% | (0.38) |
| FY2016 | 15.4% | 6.77 |
Against its own ten years
Low 8.67%
High 24.3%
Ten-year median
15.4%
Current reading's percentile
100
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| IDXX IDEXX Laboratories, Inc. | 27.2% |
| MTD Mettler-Toledo International, Inc. compare | 20.9% |
| ILMN Illumina, Inc. compare | 20.7% |
| A Agilent Technologies, Inc. compare | 17.2% |
| IQV IQVIA Holdings Inc. compare | 13.3% |
| DGX Quest Diagnostics Incorporated compare | 11.7% |
| WAT Waters Corporation compare | 7.89% |
| NTRA Natera, Inc. compare | 3.11% |
| GH Guardant Health, Inc. compare | −20.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on IDXX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement